Preliminary data from two clinical trials using the antiviral drug Remdesivir to treat COVID-19 patients are encouraging, researchers report.
One trial provides the drug to moderately ill patients and the other focuses on severely ill patients. Multiple patients they are recovering and have been discharged from the hospital. While it’s too early to tell, the researchers said there are also indications that remdesivir may avoid being put on a ventilator.
“Initial results are promising, and that’s important right now. Much of what we are learning about managing COVID-19 is focused on preventing rapid deterioration. Timing is everything. I can’t say for sure that [los pacientes] they would have been intubated otherwise, but it’s encouraging, “ He said Katherine Perez, an infectious disease pharmacist who is a co-leader of the trials.
Houston Methodist Hospital was the fifth site in the United States to join clinical trials with Remdesivir, and began enrolling and treating patients in mid-March. Now these phase 3 trials will evaluate the effectiveness and safety of Remdesivir. Both trials are registered in the federal government’s clinical trial registry.
Patients with moderate disease receive five or 10 days of treatment with remdesivir, while those with severe disease receive 10 days of treatment with the drug. Prompt treatment is critical, said the Dr. Kevin Grimes, infectious disease physician and co-leader of the trials.
“If given early enough, we expect remdesivir to interfere with the virus and block its ability to replicate in patients’ cells.”Grimes said in a Houston Methodist news release. “The goal is to avoid the deadly inflammatory cascade that leads to respiratory failure and the need to intubate and put on a respirator.”
You like me? Share it!
By Robert Preidit, HealthDay